For more than 80 years, men have been told that testosterone fuels prostate cancer. But a more nuanced picture has emerged ...

Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint Orion and ...

Prostate cancer is still associated with fear and social stigma, despite being the second most common cancer among men and one that needs attention. A urologist explained that advances in treatment ...

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic ...

There is a shadow disease that often lurks unnoticed, growing quietly within a man’s body which is hidden behind the mundane routine of daily life, masked by ag ...

The state of prostate cancer in the U.S. is not exactly great. Just take a look at the “Prostate cancer statistics, 2025” report from the American Cancer Society, published at the beginning of ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Subscribe to our newsletter for the latest sci-tech ...